Physician profile
James W Miller
NPI 1013026178
$956.82
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $178 · 2021: $228 · 2022: $19.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $164.91 | 2019-2021 | |
| Novo Nordisk INC | $153.19 | 2019-2022 | |
| Pfizer INC. | $128.36 | 2019-2020 | |
| Amgen INC. | $115.79 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $112.20 | 2019 | |
| Allergan, INC. | $77.01 | 2019-2020 | |
| Lilly USA, LLC | $35.61 | 2019-2020 | |
| Sanofi Pasteur INC. | $28.94 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.92 | 2019 | |
| Glaxosmithkline, LLC. | $22.84 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $15.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.89 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.55 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.55 | 2021 | |
| Genentech USA, INC. | $11.81 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $11.79 | 2019 | |
| Medtronic, INC. | $11.53 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.